NCT01199341

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily) for Two Weeks and Single Doses of Warfarin (25 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Warfarin and the Effect of AZD1981 on Warfarin Pharmacodynamics in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to determine whether the treatment with AZD1981 affect the exposure of Warfarin.

Conditions

• Pharmakokinetic

Interventions

Type	Name	Description
DRUG	AZD1981	100 mg per oral, twice daily for 14 days
DRUG	Warfarin	10 x 2.5 mg per oral, once daily at day 1 and day 15
DRUG	AZD1981	4 x 100 mg per oral, twice daily for 14 days

Timeline

• Start date: 2010-10-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2010-09-10
• Last updated: 2011-02-09

Locations

1 site across 1 country: Sweden